Within the framework of the conference, leading specialists in cardiology from Belarus, Russia, Germany, USA, Serbia, Kazakhstan, Italy, Canada shared their knowledge and experience.
At the conference “ACADEMPHARM” presented the first Belarusian anticoagulant “RIVAKSAN”. Doctors of Belarus noted the positive experience of using RIVAKSAN in their practice.
The release of a new dosage of RIVAXAN 2.5mg No. 60 was announced.
To buy Rivaxan 2.5 mg follow the link https://tabletka.by\Риваксан
To learn more about RIVAXAN, follow the link https://pro-tromboz.by/rivaksan.php
This form of release is intended for the prevention of atherothrombosis in adult patients after acute coronary syndrome (ACS) with an increase in cardiac biomarkers; as well as for the prevention of atherothrombotic complications in adult patients with coronary artery disease (CAD) or symptomatic peripheral arterial disease (PAD) with a high risk of ischemic events.
RIVAXAN 2.5 mg No. 60
- prevention of atherothrombotic complications in adult patients with coronary artery disease (CHD) or symptomatic peripheral arterial disease (PAD) with a high risk of ischemic events
- prevention of atherothrombosis in adult patients with acute coronary syndrome (ACS) with increased cardiac biomarkers
RIVAXAN 2.5mg is taken orally, one tablet twice a day, regardless of food intake, in combination with a daily dose of acetylsalicylic acid in accordance with the doctor’s recommendations.
Medicines “ACADEMFARM” help to preserve, strengthen and restore the health of the population of the Republic of Belarus.
“ACADEMPHARM” – we take care of the main thing!
